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Abstract
Background: Bone metastases are a common painful and debilitating consequence of castration-resistant prostate
cancer (CPRC). Bone pain may predict patients’ prognosis and there is a need to further explore CRPC patients’
experiences of bone pain in the overall context of disease pathology. Due to the subjective nature of pain,
assessments of pain severity, onset and progression are reliant on patient assessment. Patient reported outcome
(PRO) measures, therefore, are commonly used as key endpoints for evaluating the efficacy of CRPC treatments.
Evidence of the content validity of leading PRO measures of pain severity used in CRPC clinical trials is, however,
limited.
Methods: To document patients’ experience of CRPC symptoms including pain, and their impact on health-related
quality of life (HRQL), semi-structured in-depth qualitative interviews were conducted with 17 patients with CRPC
and bone metastases. The content validity of the Present Pain Intensity (PPI) scale from the McGill Pain
Questionnaire (MPQ), and the ‘Average Pain’ and ‘Worst Pain’ items of the Brief Pain Inventory Short-Form (BPI-SF)
was also assessed.
Results: Patients with CRPC and bone metastases present with a constellation of symptoms that can have a
profound effect on HRQL. For patients in this study, bone pain was the most prominent and debilitating symptom
associated with their condition. Bone pain was chronic and, despite being generally well-managed by analgesic
medication, instances of breakthrough cancer pain (BTcP) were common. Cognitive debriefing of the selected PRO
measures of pain severity highlighted difficulties among patients in understanding the verbal response scale (VRS)
of the MPQ PPI scale. There were also some inconsistencies in the way in which the BPI-SF ‘Average Pain’ item was
interpreted by patients. In contrast, the BPI-SF ‘Worst Pain’ item was well understood and interpreted consistently
among patients.
Conclusions: Study findings support the importance of PRO measures of pain severity as key endpoints for
evaluating the efficacy of treatments for CRPC, particularly for patients with bone metastases where episodes of
BTcP are common. Qualitative evidence from CRPC patients supports the content validity of the BPI-SF ‘’Worst Pain’
item and promotes use of this item for measuring pain severity in this population.
Background
Prostate cancer is the second most common cancer in
men with a worldwide age-standardised incidence rate
(ASR) of 28.1 per 100,000 [1]. It is often a slow-growing
cancer but, despite treatment, spread of cancerous cells
to other sites in the body occurs frequently [2]. Hormo-
nal therapy in the form of androgen blockade/
suppression can limit disease progression in patients
with advanced metastatic prostate cancer, but many
patients become resistant to such therapy within 1.5-3.0
years of commencing treatment [3]. The development of
castration-resistant prostate cancer (CRPC) is associated
with rapid disease progression, such that survival rarely
exceeds 9-12 months [4]. Indeed, almost all deaths
resulting from prostate cancer can be attributed to cas-
tration-resistant disease [5].
Bone metastases occur in more than 90% of men with
CRPC [6] and, as a result of tumor deconstruction of
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patients experience considerable pain [7]. Furthermore,
bone metastases may lead to skeletal-related events,
such as hypercalcaemia bone fractures and spinal-cord
compression, which can also increase pain and may
impair patients’ physical functioning and health-related
quality of life (HRQL) [8-10].
Pain has been identified as an important indicator of
overall survival in men with metastatic CRPC [11,12].
Despite the existence of guidelines for cancer pain man-
agement, pain is often under treated in cancer patients
[13,14], which may in part be because of the difficulties
in assessing pain in a valid and reliable manner. Physi-
cians often underestimate patients’ experience of pain
[15] and, in the absence of a biomarker for pain assess-
ment, patient reported outcome (PRO) measures have
become the dominant outcome measures in pain assess-
ment as they reflect the inherently subjective nature of
pain [16].
While it is widely recognized that pain is a multi-
dimensional construct [17], a unidimensional approach
centered on regular assessments of pain severity via
PRO measures been adopted in chronic pain trials for
many years [16]. Pain severity is frequently the most
important contribution to cancer patients’ experience of
pain, as demonstrated by its interference with quality of
life and daily functioning [15,18]. As such, assessment of
pain severity by short, user-friendly measures adminis-
tered on a regular basis, allows cancer patients’ experi-
ences of the evolution of pain to be captured and
quantified.
Two of the most commonly implemented self-com-
pleted measures of pain severity in clinical research are
the McGill Pain Questionnaire Short-Form (MPQ-SF)
[19,20] and The Brief Pain Inventory Short-Form (BPI-
SF) [21]. The MPQ-SF measures the sensory, affective,
and evaluative components of pain and comprises 15
items, including a 6-point verbal rating scale (VRS) ask-
ing patients to rate their present pain intensity (PPI)
using one of six descriptors (0 - No pain, 1 - Mild, 2 -
Discomforting, 3 - Distressing, 4 - Horrible, 5 - Excru-
ciating). The BPI-SF assesses pain severity (four items)
and pain interference (11 items). Pain severity is mea-
sured through patients’ rating of their level of current
pain, average pain, least pain in the last 24 hours and
worst pain in the last 24 hours, using an 11-point
numerical rating scale (NRS) ranging from 0 (no pain)
to 10 (pain as bad as you can imagine). Although these
four items can be used to form a composite score of
pain intensity, the ‘Worst Pain’ and ‘Average Pain’ items
of the BPI-SF are often used in clinical trials to singly
represent pain severity [21] as supported by the Initia-
tive on Methods, Measurement, and Pain Assessment in
Clinical Trials (IMMPACT) [16,22,23].
When selecting a PRO measure for use in clinical
trials to document treatment benefit, it is necessary to
demonstrate that the selected measure is fit for its
intended use in a specific context of use [24]. A key
consideration in this regard is evidence of content valid-
ity (i.e. that the measure captures concepts that are of
importance and clinical relevance to patients and in a
manner that is comprehensive, relevant and comprehen-
sible to patients) [24,25]. Documentation of the content
validity of a measure is specific to its context of use,
including but not limited to the population of interest,
and is typically established through the generation of
evidence from qualitative research comprising patients
whose clinical and demographic characteristics are simi-
lar to those of the patients enrolled in the respective
clinical trials.
Recent research has provided insight into the experi-
ences of patients with CRPC, however there is a need to
further understand the experiences of CRPC patients
with bone metastases, particularly with regard to
patients’ experience of pain [26,27]. Furthermore, while
patients experiencing pain were involved in the develop-
ment of both the MPQ and BPI-SF, there is currently
no available evidence of the content validity of these
measures for use in CRPC patients with bone
metastases.
The present study, therefore, had two main aims: 1.)
To investigate, via qualitative research, the experiences
of patients with CRPC and bone metastases, particularly
in regards to patient experiences of bone pain and
resulting HRQL impact 2.) To assess the content validity
of the MPQ-SF PPI and the BPI-SF ‘Average Pain’ and
‘Worst Pain’ items within this population.
Methods
Study design
Face-to-face in-depth qualitative interviews were con-
ducted with 17 patients with CRPC and confirmed bone
metastases. A combined approach was taken whereby
the interviews included a detailed concept elicitation
phase followed by thorough cognitive debriefing of the
selected pain measures.
Patient recruitment
Patients eligible for participation in the study were
recruited in the United States with the help of clinicians
from two clinical practices and advertisements from a
commercial recruitment agency. To be eligible for parti-
cipation in the study, patients had to have a clinician-
confirmed diagnosis of CRPC with documented evi-
dence of bone metastases (CRPC M1) and be at least 18
years or age. Participants were also expected to be cur-
rently experiencing bone pain or to have experienced
bone pain recently. Exclusion criteria included evidence
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trolled systemic disease, or any other significant clinical
disorder.
Ethics
The study was conducted in accordance with the
Declaration of Helsinki, and was approved by an Inde-
pendent Review Board. Written informed consent was
obtained from all patients prior to entry into the study.
Interview methods
All interviews were conducted by trained interviewers
using a semi-structured interview guide. The interview
guide was informed by consideration of prostate cancer
literature as well as published articles documenting the
development and validation of the MPQ-SF and BPI-SF.
During the initial ‘concept-elicitation’ phase of the inter-
view, patients were asked a series of open-ended ques-
tions (e.g. could you describe for me your experiences
of prostate cancer?) designed to investigate their experi-
ence of symptoms related to CRPC and bone metastases
(with particular focus on pain). At this stage, care was
taken to avoid the use of leading questions, in order to
ensure that patients’ spontaneous responses were
captured.
In the second ‘cognitive debriefing’ phase of the inter-
view, patients were asked to complete the MPQ-SF PPI,
and the BPI-SF Average Pain and Worst Pain items as
part of a ‘think-aloud’ exercise in which patients were
encouraged to vocalize their decision making process
when selecting response choices for each of the mea-
sures. Patients were then asked detailed questions
designed to verify the relevance and level of clarity (i.e.
absence of ambiguity, understanding of terms) of the
measures, and to confirm that the items and response
options measured pain intensity adequately (e.g. in your
own words what is this question asking? How did you
decide which answer to give?). Patients were also asked
to identify which of the three PRO measures best docu-
mented their experience of bone pain. Again the line of
questioning was designed so to not lead or bias patient
responses.
A pilot interview was conducted with one patient and,
based on that patient’s feedback, the interview guide
was shortened and refocused. An interim analysis of the
data collected from this interview and the subsequent
10 interviews was also conducted (Round I), after which
the interview guide was revised to incorporate additional
questions designed to further explore the terminology
that patients used to describe the pain that they experi-
enced and patient understanding and interpretation of
the selected PRO measures in the final 6 interviews
(Round II).
Qualitative analysis
All interviews were audio-taped and transcribed verba-
tim for the purpose of qualitative analysis. Written
interview transcripts were then entered into a qualitative
software package (Atlas.Ti) which was used to facilitate
the analysis of interview transcripts.
Patient responses during the open-ended concept eli-
citation phase of the interview were analysed using a
Grounded Theory approach whereby sections of tran-
scripts from individual patients (i.e. quotes) were
assigned codes reflective of underlying concepts [28,29].
In this approach, the meaning of concepts are discov-
ered via the words and actions of participants from the
ground up, rather than from application of a priori the-
ory or understanding [30]. This approach is particularly
useful where, as here, the intention is to build an overall
picture of patients’ experience and to understand the
way in which elicited concepts interrelate with one
another. In contrast, qualitative analysis of patient
responses during ‘cognitive debriefing’ focussed specifi-
cally on whether the concepts and items comprising the
selected PRO measures were relevant, appropriate and
understood by patients in the way in which the develo-
pers had originally intended [24].
Interview transcripts were coded and analysed by ana-
lysts trained in qualitative analysis techniques. To ensure
consistency among analysts, a provisional analysis of the
first three transcripts in Round I was conducted by all
analysts and a reliable coding scheme was then devel-
oped based on consensus among analysts. Although the
primary purpose of qualitative research is not to assess
concept frequency, a count of the number of patients
who mentioned a given concept at least once during an
interview was recorded during the process of analysis in
order to provide an indicator of the relative importance
of each concept within the study sample.
There exist no definitive guidelines regarding recom-
mended sample sizes for qualitative studies and avail-
able guidance actually states that the number of
patients is not as critical as interview quality, with
sample size depending on the completeness of infor-
mation obtained from the analysis of interview tran-
scripts [24]. That the concepts elicited by patients had
been fully explored during the interviews was assessed
by confirmation of conceptual saturation. Saturation is
d e f i n e da st h ep o i n ta tw h i c hn on e wr e l e v a n to r
important information emerges with the collection of
more data [24,28,31] and recent investigations suggest
that conceptual saturation is typically achieved within
12-13 interviews [31,32]. Sample sizes of this magni-
tude are also considered to be generally acceptable for
confirmation of user understanding of PRO measures
via cognitive debriefing.
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Patient Demographic and Clinical Characteristics
Seventeen men with CRPC participated in this qualitative
research study. The average age of men participating in the
study was 71 years (range 53-86) and all but one participant
were Caucasian. On average, participants had been diag-
nosed with prostate cancer for 7 years and had bone metas-
tases for 1.7 years. The sample included patients with well
differentiated, moderately differentiated and poorly differ-
entiated or undifferentiated cancer, as defined by Gleason
scores [33]. All patients were receiving medication for pain
relief and only two patients (12%) reported experiencing
more than moderate bone pain, as assessed by ratings on a
5-point Likert-type scale (very mild - very severe) com-
pleted on the day of the interview. Demographic and clini-
cal characteristics of the sample are displayed in Table 1.
Concept Elicitation Phase: Patients’ experiences of CRPC
and bone metastases
Patients’ experiences of bone metastases associated with
CRPC and/or its treatment comprised a constellation of
symptoms of which bone pain, fatigue and low energy
were predominant. CRPC localized symptoms mani-
fested as urinary-related symptoms such as increased
urinary frequency, urinary incontinence, pain upon uri-
nating and difficulties initiating or maintaining urinary
flow. Difficulties in getting or maintaining an erection
were also reported by some patients. Further issues
mentioned by patients included gastrointestinal distur-
bances (such as constipation, diarrhea, bloating and nau-
sea/vomiting), hot flashes (fever/sweats/chills) and
changes in taste perception, appetite and weight. How-
ever, these issues were largely attributed by patients as
being side effects of their current treatment regimens.
Consideration of qualitative data obtained during the
interviews revealed that no new concepts were elicited
as data collection neared completion (Table 2). All con-
cepts were first elicited during round I of the interviews,
with approximately 85% of concepts elicited within the
first five interviews. This suggests that conceptual
saturation of CRPC-related signs and symptoms was
achieved within this sample.
In accordance with main study aims, patients’ experi-
ences of bone pain were thoroughly explored. This
symptom was spontaneously mentioned by 16/17
patients during open-ended discussion which highlights
the importance of this concept for patients. Feedback
from patients during these interviews suggests that
patients were able to distinguish pain caused by bone
metastases from other types of pain based not only on
the location of the pain but also the intensity and tem-
poral features of the pain including onset, frequency and
duration: ’The pain that I have, it’s a really different
pain. And I’ve had pain before in my life. But it’ss od i f -
ferent, because it’s very intense. It’s very severe. It really
hurts’. Bone pain was often localized in the lower back
or ‘tailbone’. Other sources of bone pain were synovial
joints (including knees, hips and shoulders) and the ribs
and neck. Whilst bone pain was the predominant form
of pain reported by patients, some patients currently
receiving treatment via chemotherapy also referred to
pain accompanied by feelings of numbness and loss of
sensation, particularly in ext r e m i t i e ss u c ha st h ef e e t :
“And I’ve had trouble with my feet - they tend to be a
little bit on the numb side, and hopefully that will dissi-
pate”. It is likely that this is indicative of chemotherapy-
induced peripheral neuropathy (CIPN), a common side-
effect associated with neurotoxic chemotherapy drugs
[34].
Patients reported that the pain they experienced was
manageable with analgesic medication such as acetami-
nophen and opioids, but never completely goes away:
‘Well, I control it somewhat with this medication that
I’m taking, so that has a lot to do with how I could say
it feels’; ‘The more medications I take, the lighter the
Table 1 Patient demographic and clinical characteristics
(n = 17)
Characteristic
Age in years, mean [range] 71.1 [53 - 86]
Mean years since prostate cancer diagnosis 7.0
Mean years since onset of bone metastases 1.7
Cancer stage*
Well differentiated (Gleason score 2-4) 2 (12%)
Moderately differentiated (Gleason score 5-7) 5 (29%)
Poorly differentiated or undifferentiated (Gleason
score 8-10)
5 (29%)
Patient-rated overall bone pain**
Very mild 3 (18%)
Mild 3 (18%)
Moderate 8 (47%)
Severe 2 (12%)
Very severe 0
Pain relief medication ***
Ibuprofen 3 (18%)
Percocet
® (acetaminophen; oxycodone
hydrochloride)
8 (47%)
Lortab
® (acetaminophen, hydrocodone bitartrate) 1 (6%)
Oxycontin
® (oxycodone hydrochloride) 5 (29%)
Tylenol
® (acetaminophen) 4 (24%)
Zometa
® (Zoledronic acid) 2 (12%)
Vicodin
® (acetominophen, hydrocodone bitartrate) 1 (6%)
Darvocet
® (acetominiphen; propoxyphen
hydrocholoride)
1 (6%)
*Missing data (n = 4) ** Missing data (n = 1) *** Patient could be receiving
multiple pain relief medications
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without pain whatsoever’. Furthermore, despite man-
agement by analgesic medication, patients did experi-
ence some variation in the level of pain experienced
which was suggestive of breakthrough cancer pain
(BTcP): ’Mine varies quite a bit. It goes from hardly
any pain at all to severe’; ‘And it’s constant... it’sj u s t
sometimes worse than other times’. BTcP is defined as
a “transient exacerbation of pain that occurs either
spontaneously or in relation to a specific predictable or
unpredictable trigger despite relatively stable and ade-
quately controlled background pain” and is typically
classified as: 1.) incident or provoked; 2.) idiopathic or
spontaneous; 3.) “end-of-dose failure” of a long acting
opioid [35,36]. Consistent with these definitions, 9/17
patients (53%) reported experiencing BTcP.
Table 2 Patient-reported signs and symptoms of CRPC
Concept Round I Round II Concept
Frequency (%)
PT
01
PT
02
PT
03
PT
04
PT
05
PT
06
PT
07
PT
08
PT
09
PT
10
PT
11
PT
12
PT
13
PT
14
PT
15
PT
16
PT
17
Bone Pain X XXXXXXXXXXXXXXX 1 6 (94)
BTcP (incident) X X X X X 5 (29)
BTcP (idiopathic) X X X X 4 (24)
BTcP ("end-of-dose failure”) X X X X X X X 7 (41)
Skeletal-related events
(fractures)
X X 2 (12)
Fatigue X X XX XXXX 8 (47)
Low energy X X X X X X X 7 (41)
Loss of strength X X X 3 (18)
Urinary dysfunction X X XXXXXXXXX X 1 2 (71)
Blood in urine X X X 3 (18)
Can’t empty bladder X X 2 (12)
Increased urinary frequency
during the day
X X X X 4 (24)
Difficulty starting urination X X X 3 (18)
Urinary incontinence X X X X 4 (24)
Weak or interrupted flow
of urine
X X X X 4 (24)
Increased urinary frequency
during the night
X X X 3 (18)
Painful or burning urination X X 2 (12)
Poor stream X X 2 (12)
Erectile dysfunction X X 2 (12)
Fever/sweats/chills X X X X X X 6 (35)
Numbness/loss of sensation X X X X 4 (24)
Altered taste perception X X 2 (12)
Loss of appetite X X X 3 (18)
Weight loss X X X 3 (18)
Weight gain X X 2 (12)
Gastrointestinal disturbance X X X X X X X 7 (41)
Bloating X X 2 (12)
Constipation X X X X 4 (24)
Diarrhea X X 2 (12)
Nausea/vomiting X X X X X 5 (29)
Anxiety X X 2 (12)
Depression X X X X 4 (24)
Note: X indicates the first time that the respective concept was elicited by a participant.
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chemotherapy, and physical activities such as gardening,
walking or standing: ‘After I went through chemotherapy
on Tuesday, the third day after chemo,...every bone in
my body from my ankles to my head was in pain and
there was no medication or any comfort that I had or
had access to that could make that pain go away. It
actually kept me bedridden for 3 days.’; ’If you’re trying
to do a whole lot, then you probably have a whole lot of
pain. If you’re not trying to do anything, you’re not going
to have much pain. Or you’re only going to have some,
but you’re not going to be as bad’. In contrast, for other
patients (n = 4) there was no apparent cause for epi-
sodes of exacerbated pain: ’I would say I just got up in
the morning, the pain was there. It was like a severe
charley horse and I just couldn’tm a k ei tg oa w a y .I
increased my medication. I took a stronger oxycodone, I
took a 20, because that will usually bring down my pain
level, but that didn’te v e na f f e c ti te i t h e r .I tw a sj u s t
there with me the whole day and gradually, I would say
over a period of 24 to 36 hours, it finally kind of worked
itself out so I could kind of walk around and live with it
again’.
End-of-dose failure, defined as pain that occurs at the
end of the timeframe in which pain medication is
intended to be effective, was commonly experienced by
patients (n = 7). Such pain was frequently responsible
for waking patients from their sleep: ’And it gives me
some relief maybe where I can drop off and sleep a little
more. And then in a couple of hours it’sb a c k . ’; ‘...what I
was doing helped a little while, but didn’tg i v em er e l i e f
for very long’. Delays in obtaining pain relief after taking
pain medication also impaired patients’ activities the
next morning: ’. . . b u ti tt a k e sm ea nh o u ro rs ot og e t
things limbered up in the mornings in there and my
drugs that I take in there to kick in.’
The pain associated with bone metastases had debili-
tating consequences on patients’ lives with patients
reporting impairments in daily functioning from a physi-
cal, emotional and social perspective. The physical
impact of bone pain typically manifested in patients’
experiences of difficulties with walking or even standing:
’The worst part is the relationship between movement
and function and this pain. Because when I just try to
do anything, I can get up out of the chair, anything like
this - I know it’s going to hurt. And it usually hurts, and
so I’ll try to minimize it as much as I can’.P a t i e n t s
reported that the experience of bone pain and associated
limitations in physical functioning meant that their abil-
ity to perform their daily activities and to engage in
their usual social activities had been affected: ‘[Bone
pain] prevents me from doing many things that I would
do, or would like to do, and normally would do, but I
don’td o .’; ‘Ic a n ’t seem to do things that I’ve always
done for myself and things that I like to do for other peo-
ple...at the present time, it’s more of a burden to me than
at any time in my life. Right now pain is affecting my
daily lifestyle.’
Further to these physical impairments, patients
reported being unable to sleep, feeling tired, and feeling
irritable because of bone pain. Patients also described
feeling depressed, anxious and stressed, particularly in
relation to BTcP when it was evident that pain was get-
ting worse: ‘The pain can immobilize you, where it
brings on depression. It brings on fear. It brings on anxi-
ety. It brings doubt...stress.’; ‘When you have pain that
strong, you can’t help but have some fears and worries
about it’.
Based on collective feedback from patients, a disease
model outlining patients’ experiences of living with
CRPC with bone metastases in the context of disease
pathology was developed (Figure 1).
Cognitive Debriefing Phase: Patients’ understanding and
differentiation of current, worst and average pain
Responses to open-ended questions regarding the per-
ception of ‘Current Pain’, ‘Worst Pain’ and ‘Average
Pain’ revealed that patients were able to distinguish
between these three distinct concepts. Patients talked
about ‘Current Pain’ as representing the intensity of
their pain ‘right now’ whereas ‘Worst Pain’ represented
the highest intensity of their pain within a given time
frame. Patients, however, provided two alternate expla-
nations of ‘Average Pain’. For example, some patients
considered ‘average pain’ to represent a value in-
between the most and least severe pain that they had
experienced over a given time frame, while others
described ‘average pain’ as representing the level of pain
experienced ‘most of the time’.
MPQ-PPI item
Most of the patients interviewed did not experience any
difficulty in understanding the term “current pain inten-
sity”, although it was evident from the responses of three
participants that they were not thinking about their “cur-
rent pain intensity” when answering this question but
were thinking back to their worst pain in the past week or
the past 24 hours: ‘Well I was thinking that that was when
it hurt at its worst, perhaps, not necessarily now it was
hurting at this particular moment, but how it hurts at its
worst time’. Hardly any difficulties were reported when
patients were asked how hard it was to select an appropri-
ate response option for this item. However, some patients
had difficulty understanding the meaning of the pain
descriptors (no pain, mild, discomforting, distressing, hor-
rible, and excruciating) and the relation of these descrip-
tors to the bone pain they experienced. Patients also found
it difficult to differentiate between the pain descriptors
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very similar, if not synonymous: ‘Yeah, the words mild and
discomforting - what’s the difference between those? And
then discomforting and distressing? Distressing is more of a
psychological thing, I would think, than a measurement of
pain. Horrible is a fear type thing instead of a measure-
ment of pain. Excruciating - that’s probably a pretty accu-
rate measurement of pain. But some of the words there -
discomforting, distressing, and horrible I don’t care for.’ To
further investigate patients’ perceptions of the response
continuum, as part of the revised interview guide, the final
6 patients interviewed were asked to assign numerical
values (from 0-10) to each pain descriptor. Patient answers
revealed that there was no standard response continuum
and that the distance between individual response options
were not interpreted as being equal, as would be expected
in a truly linear scale (Figure 2).
BPI-SF ‘Worst Pain’ and ‘Average Pain’ items
Patients appeared to experience very little difficulty
understanding the BPI-SF ‘Worst Pain’ item, correctly
interpreting that they were to answer the item by indi-
cating the severity of worst pain experienced in the past
24 hours: ’At the time that my pain was the worst in the
last 24 hours, how would I rate that pain as far as
everything that I’ve experienced in my life, from no pain
to pain as bad as you can imagine. I would say that my
pain the last 24 hours was a seven’. Patients were asked
to define levels of meaningful improvement or worsen-
ing in pain using their initial scores as a reference point.
New scores provided by all but one patient reflected
improvements or worsening in pain where appropriate,
with responses indicating that increments or decrements
of 2 to 3 points would be considered meaningful.
In deciding on their average pain, 11 patients based
their decision on the value between their worst pain and
least pain over the specified recall period (’Well, to me,
that’s taking the worst pain you had in the last while
and the lowest one and kind of average them out over a
timeframe’) while 6 patients based their decision on the
level of pain that they experienced ‘most of the time’ (’I
don’t know. I guess average is what it is most of the time.
Urinary Dysfunction  Bone Pain  Skeletal Related 
Events 
 Vertebral 
fracture 
 Non-vertebral 
fracture 
 Urinary frequency 
 Urinary hesitance 
 Incontinence 
 Nocturia 
 Poor stream 
 Dysuria 
 Fatigue 
 Low energy 
 Loss of strength 
 Numbness 
 Loss of 
sensation 
 Diarrhea 
 Constipation 
Intensity/Severity  Temporal Features  Present/Absent  Present/Absent 
Other Signs 
  Fatigue 
 Low energy 
 Loss of strength 
 Erectile dysfunction 
 Weight loss 
Castration Resistant Prostate 
Cancer (CRPC) 
Primary Site  Bone Metastases 
Treatment 
Side Effects 
Other Metastases 
Signs & Symptoms 
Present/Absent 
 Background 
 Breakthrough: 
 Incident 
 Idiopathic 
 End-of-dose 
Analgesic Use 
 Bloating 
 Nausea 
 Vomiting 
 Fever/sweats/  
chills 
 Altered taste 
 Loss of appetite 
 Weight gain 
 Mobility 
 Exercise 
 Energy 
 Vitality/tiredness 
 Sleep quality 
 Depression 
 Worry/ Anxiety 
 Stress 
 Social life 
 Relationships 
 Self-care 
 Work limitation 
 Activities of daily 
living 
Impact 
Physical  Energy  Emotional  Role Functioning 
 Sleep quality 
Sleep 
 Diminished sex life 
Sexual Functioning 
Figure 1 Disease model of patients’ experience of CRPC with bone metastases.
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t h i n gl i k et h a t ,i t ’sa r o u n daf i v e ’). Recall time for aver-
age pain varied between patients (’since beginning
treatment’; ‘last week’; ‘last 24 hours’) and patients
recommended including a clear timeframe for clarity.
Again patients indicated that increments or decrements
of 2 to 3 points for average pain would be considered
meaningful. When asked, patients identified scores of 1-
3 as representing an acceptable level of pain, and scores
of 7-9 as representing an unacceptable level of pain.
When asked which of the presented items they pre-
ferred, one patient had no preference while all other
patients preferred the items from the BPI-SF: ‘The brief
pain inventory, because it’s simpler to answer, it’se a s i e r
to read, and it stands out.’; ‘Il i k et h eb r i e fp a i ni n v e n -
tory better because I can relate to - like I said, I didn’t
care for the words discomforting, distressing, and horri-
ble.’ Some patients commented that the BPI-SF Worst
Pain item was a more accurate reflection of the degree
of pain experienced (’I’m lucky that I have a lot of time
that I don’t have very much pain, but there are times
where I have quite fairly severe pain, so an average
really isn’t an accurate picture’), while others preferred
the BPI-SF Worst Pain item because it was easier to
recall (’I think three is a little more useful, the one about
your worst pain in the last 24 hours, because it’s more in
your mind, more present in your mind’). A similar num-
ber of patients considered that, because of fluctuating
pain levels, the BPI-SF Average Pain item was a better
indicator of pain experienced: ’I think average, probably,
for the simple reason that I don’t think I have that many
episodes of really bad pain. I think mine is more on the
same level or plane most of the time’.
Discussion
Based on qualitative evidence from CPRC patients with
bone metastases, a disease model outlining the experi-
ences of such patients in the context of disease pathol-
ogy has been developed. Such models are valuable in
terms of identifying key measurement concepts which
can be used to demonstrate treatment benefit, providing
insight into how best to measure these particular con-
cepts and providing a contextual basis for interpreting
study findings [37]. As evident within this model,
Patient 12
Patient 13
Patient 16
Patient 14
Patient 15
Figure 2 Patients’ representation and rating of the descriptors from the McGill Pain Questionnaire– Present Pain Intensity (Round II).
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Page 8 of 11among the constellation of symptoms experienced by
patients with metastatic CRPC, pain (and specifically
bone pain) is of paramount importance. This is consis-
tent with previous qualitative and clinical studies where
pain is reported to be the most frequently observed
symptom among CRPC patients [26,27]. Findings from
this study reveal that pain associated with bone metas-
tases is chronic in nature, but generally well-managed
by analgesic medication. Episodes of BTcP, however, are
common and particularly debilitating for patients.
Patients in the present study reported experiencing wor-
sening of pain in response to mild physical exertion or
particular activities of daily living (e.g. walking to the
station, standing up), as a result of end of dose failure of
analgesic medication and in some instances for no dis-
cernable reason at all.
Given the fluctuating nature of pain associated with
bone metastases, subjective reporting of pain is time
dependent. Multiple reports of pain over time allow
integration of symptom evolution in the assessment of
patients’ pain severity. For repeated use, the PRO mea-
sure selected for pain assessment should be short and
easy for patients to complete. In this study cognitive
debriefing of three single-item measures of pain severity
commonly included as endpoints in oncology clinical
trials, the MPQ-SF PPI item and ‘Average Pain’ and
‘Worst Pain’ items of the BPI-SF, was conducted to
determine content validity in patients with CRPC.
Whilst the majority of patients were able to accurately
interpret the concept of ‘current pain’ (assessed by the
MPQ-SF PPI item), due to the fluctuating nature of
pain experienced by CRPC patients with bone metas-
tases, assessments of ‘current pain’ may not be the most
accurate or informative way of assessing pain severity in
this population. Indeed, previous research has high-
lighted that ratings of current pain, among patients
experiencing persistent pain, are often lower than rat-
ings of recalled worst or average pain over a given time-
period [38].
The concept of ‘worst pain’ appeared to be interpreted
correctly and consistently among patients. By contrast,
however, there appeared to be some variability in the
way in which patients interpreted the concept ‘average
pain’. Without consensus among patients regarding the
definition of average pain, it would be difficult to deter-
mine whether differences among patients are a true
reflection of individual differences in pain experience or
a result of variations in interpretation of the concept by
patients, ultimately limiting the validity of such assess-
ments. As such, ‘worst pain’ may be the most appropri-
ate measure of pain severity for use in clinical trials.
Furthermore, there is evidence to suggest that ratings of
‘worst’ pain are more representative of the burden
experienced by patients in relation to pain and may be
more reliable to report; given that when a patient with
persistent pain thinks back to their pain over a period of
time, they tend to focus their response on their ‘worst
pain’ even when asked about their ‘average pain [38,39].
Reduction of ‘worst pain’, therefore, can be seen as a
key indicator of treatment efficacy for patients.
Feedback from patients regarding the different rating
scales adopted by the MPQ-SF PPI (0-6 VRS) and BPI-
SF (0-10 NRS) highlighted the superiority of NRS rat-
ings scales for the assessment of pain severity. It
appeared to be challenging for patients to define and
distinguish between the pain descriptors used in the
MPQ-SF PPI scale and there was little or no consensus
among patients regarding the grading of each response
option. As a result, the MPQ PPI scale could be
expected to demonstrate limited sensitivity to changes
in the level of pain experienced by patients. Indeed, the
limited sensitivity of VRS scales to clinical changes is a
commonly held weakness of the use of such measures
in pain assessment [40].
By contrast, patients experienced little or no difficulty
rating the worst or average pain using a 0-10 NRS.
From a measurement perspective, the use of an 11-point
NRS scale to measure pain severity provides a simple,
non-burdensome response format that is likely to be
reliable and sensitive to change [40,41]. NRS scales have
demonstrated greater levels of sensitivity and discrimi-
natory power than VRS scales [42]. In addition the stan-
dardised format with which NRS scales are applied
across cultures and languages (typically an 11-point 0-
10 scale) means that patients are familiar with this man-
ner of assessment; as opposed to formulations of VRS
scales which can often vary in the number of designated
response options and the labels assigned to these
response options [42]. Patient familiarity of NRS
response scales is also reflected in patient estimates of
meaningful differences on such scales (2-3 points) which
are not only similar for ratings of average pain and
worst pain in this study but also evaluations of clinically
meaningful difference on 0-10 NRS pain severity mea-
sures implemented in other conditions [43]. Published
recommendations for core outcome measures in clinical
chronic pain trials also support the use of 0-10 NRS
scales for assessing pain severity [16].
One limitation, attributable to both the MPQ-SF and
BPI-SF is that they do not provide opportunity for
patients to differentiate the different forms of pain that
they may experience. Feedback from the patients inter-
viewed suggested that they were able to distinguish
bone pain from other types of pain such as that asso-
ciated with CIPN based on the location and nature of
this pain, however it is not clear when completing an
overall pain assessment whether patients would take
into account only the pain associated with bone
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Page 9 of 11metastases or all types of pain experienced. There is a
chance therefore, that in the context of a clinical trial,
improvements in patients’ experiences of bone pain may
be “washed out” by accompanying neurotoxic side-
effects such as CIPN.
Nonetheless, however, from a content validity perspec-
tive, evidence supports the use of the BPI-SF ‘Worst
Pain’ item as the most appropriate measure of pain
severity in CRPC patients. In addition to demonstrating
acceptable content validity in patients with CRPC, a
review of evidence in relation to the BPI-SF ‘Worst
Pain’ item also suggests that this item fulfils much of
the key criteria specified in the recent FDA PRO Gui-
dance for Industry [24,44]. In particular, there is a
wealth of evidence supporting the psychometric validity
of this item [45-48]. Further research, however, is
needed to confirm these measurement properties within
patients with CRPC and bone metastases.
Conclusions
Among the constellation of symptoms experienced by
CRPC patients with bone metastases, bone pain is of
key concern. There is, therefore, the need for a reliable
and valid measure of pain severity within this popula-
t i o n .T ot h i se n d ,t h eB P I - S FW o r s tP a i ni t e mh a s
demonstrated strong content validity in these patients
and, whilst psychometric validity of this item in CRPC
patients is to be confirmed, there is considerable evi-
dence from comparable disease areas to support the
psychometric properties of this item. A culmination of
available evidence suggests, therefore, that the BPI-SF
‘Worst Pain’ item is an appropriate measure of pain
severity for use as a clinical trial endpoint for evaluating
treatment efficacy in patients with CRPC and bone
metastases.
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